Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSAT with Ultrasensitive RDTs for Malaria Elimination in Myanmar
NCT04093765Completed
- Sponsor
- University of Oxford
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of dihydroartemisinin + piperaquine and primaquine in Plasmodium falciparum malaria (2 arms), sponsored by University of Oxford. Primary endpoint: Adjusted incidence rate ratio before/after MSAT at 12 months. Started Nov 2018; status: completed.
02
Drugs
dihydroartemisinin + piperaquineprimaquine
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT04093765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093765.